Results 181 to 190 of about 63,292,925 (286)

Circulating miR-221/222 and Serum IL-23 in Treatment-Naïve Multiple Sclerosis: A Case-Control Study. [PDF]

Medicina (Kaunas)
Sarı US, Tepe N, Solmaz Avcıkurt A, Uysal S, Bolat H, Eşmeli F.   +5 more
europepmc   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Comparative Effects of IL-17 and IL-23 Inhibitors on Lipid Profiles and Lipid-Derived Atherogenic Indices in Patients with Psoriasis. [PDF]

Pharmaceuticals (Basel)
Celik C, Çelik MS, Cepik N.
europepmc   +1 more source

Smaller is better: nanobodies meet NMR

FEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. [PDF]

Dermatol Pract Concept
Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB.   +4 more
europepmc   +1 more source

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

FEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng, Shen‐Shin Chang, Feng‐Wei Chen, Ying‐Chieh Su, Thanh Phuong Nguyen, Yu‐Wei Hsiao, Jhih‐Ying Chi, Hsin‐Yin Liang, Ju‐Ming Wang   +8 more
wiley   +1 more source

PO:01:010 | Survival of second-line treatment with tnf inhibitors vs il-23 inhibitors after failure of a first tnf inhibitor: a real-life observational study from the italian multicenter birra cohort in patients with psoriatic arthritis

Reumatismo
Background. Since 2021, IL-23 inhibitors (IL-23i) such as guselkumab, and since 2022 risankizumab, have been available for the treatment of psoriatic arthritis (PsA). However, after failure of a first tumor necrosis factor inhibitor (TNFi), switching to
Società Italiana di Reumatologia
doaj  

Oral delivery of recombinant <i>Lactococcus lactis</i> expressing an IL-23 inhibitor as a potential therapeutic strategy for experimental colitis. [PDF]

Drug Deliv
Kopecna E, Raskova Kafkova L, Kosztyu P, Sloupenska K, Zachova K, Cutkova A, Skarda J, Vaculova J, Kuchar M, Panova N, Walimbwa S, Plavec TV, Berlec A, Maly P, Raska M.   +14 more
europepmc   +1 more source

DNA ligase LigE increases bacterial transformation with damaged extracellular DNA

FEBS Letters, EarlyView.
The DNA ligase LigE from the naturally competent Gram‐negative bacterium Neisseria gonorrhoaea increases transformation with cut extracellular DNA. This process is ATP‐dependent and relies on the catalytic activity of LigE; it also requires that LigE contains an intact periplasmic localisation sequence, indicating that ligE functions in the periplasm ...
Jolyn Pan, Avi Singh, Shrawani Weralupe Gamladdalage, Joanna Hicks, Adele Williamson   +4 more
wiley   +1 more source

Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review. [PDF]

Medicine (Baltimore)
Afzal MW, Haseeb A, Ali U, Ashraf MR, Mehmood A, Perveen A.   +5 more
europepmc   +1 more source